Previous 10 | Next 10 |
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2019 Earnings Conference Call August 07, 2019 04:30 PM ET Company Participants Melissa Forst - Vice President, Argot Partners Briggs Morrison - Chief Executive Officer Rick Shea - Chief Financial Officer Michael Meyers - Chief Medical Offi...
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Syndax Pharmaceuticals (NASDAQ: SNDX ): Q2 GAAP EPS of -$0.47 misses by $0.02 . More news on: Syndax Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WALTHAM, Mass. , Aug. 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2019 . In addition,...
WALTHAM, Mass. , Aug. 5, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison , M.D., Chief Executive Of...
WALTHAM, Mass. , July 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2019 ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 114 weeks of public selections as part of this ongoing live forward-testing. In...
Thinly traded micro cap Syndax Pharmaceuticals (NASDAQ: SNDX ) is up 6% premarket on light volume in reaction to the FDA's sign-off on its IND for an open-label Phase 1/2 clinical trial evaluating SNDX-5613 in patients with relapsed/refractory acute leukemias. More news on: S...
WALTHAM, Mass. , July 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investig...
Shares of Syndax Pharmaceuticals ( SNDX ) have fallen by 12% since my article from January of last year stated that the company was in for a potentially transformative 2018. So far in 2019, the stock has posted a 95% gain as optimism returned to the name as Wall Street focuses on renewed pro...
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...